Results 151 to 160 of about 161,535 (242)

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source

Manipulating the delivery and immunogenicity of DNA vaccines through the addition of CB[8] to cationic polymers. [PDF]

Mol Ther Nucleic Acids
Sallah HJ, Cheesman BT, Peeler DJ, Howe AM, Shattock RJ, Coulston R, Tregoning JS.   +6 more
europepmc   +1 more source

Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study

British Journal of Clinical Pharmacology, EarlyView.
Aim We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish ...
Sofia Attelind, Niclas Eriksson, Marco Cavalli, Yiyi Xu, Fredrik Nyberg, Anders Sundström, Mia Wadelius, Pär Hallberg   +7 more
wiley   +1 more source

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients

British Journal of Clinical Pharmacology, EarlyView.
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly ...
Clara Laffitte Redondo, Venceslas Bourdin, Abd El Kader Ait Tayeb, Sihem Benaboud, Inès Martins, Caroline Joyau, Myriam Benhamida, Isabelle Sermet‐Gaudelus, Clémence Martin, Pierre Régis Burgel, Céline Verstuyft, Laurent Chouchana, Estelle Ayme‐Dietrich   +12 more
wiley   +1 more source

Pichia pastoris-Derived β-Glucan Capsules as a Delivery System for DNA Vaccines. [PDF]

Vaccines (Basel)
Pinho SS, Invenção MDCV, Silva AJD, Macêdo LS, Espinoza BCF, Leal LRS, da Gama MATM, Moura IA, Silva MEDS, Souza DVS, Lara ML, Alves JNSA, Freitas AC.   +12 more
europepmc   +1 more source

MT‐RNR1 genotype testing for preventing aminoglycoside‐mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Aminoglycosides are broad‐spectrum antibiotics used in the management of severe infections. Aminoglycosides are associated with nephrotoxicity and ototoxicity. Although dosing strategies such as once‐daily administration and therapeutic drug monitoring have reduced the incidence of nephrotoxicity, ototoxicity remains unpredictable and may occur at ...
John H. McDermott, Sian Hilton, Cinzia Dello Russo, Nicola Booth, Simon Drysdale, Philip Howard, Stephen Hughes, Mallinath Chakraborty, Helen McDevitt, Charlotte Alston, Maya Desai, Mike Beadsworth, Adam Reynolds, Serim Min, Katherine Payne, Munir Pirmohamed, William G. Newman   +16 more
wiley   +1 more source

Advanced biopolymeric materials and nanosystems for RNA/DNA vaccines: a review. [PDF]

Nanomedicine (Lond)
Pereira LFT, Tredus JGR, Corá LO, Novacki LL, Oliveira GED, Vodiani M, Dias IP, Filho RXV, Picheth GF.   +8 more
europepmc   +1 more source

Continuous Purification of mRNA Produced by In Vitro Transcription Using High Performance Countercurrent Membrane Purification

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Messenger ribonucleic acid (mRNA) therapeutics produced by in vitro transcription must be purified to remove residual enzymes and free nucleotides. This study examines the use of high‐performance countercurrent membrane purification (HPCMP) for the purification of mRNA therapeutics based on differences in the rate of diffusion across ...
Ziqiao Wang, Amin Javidanbardan, Ali Behboudi, Andrew L. Zydney   +3 more
wiley   +1 more source

Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity. [PDF]

Hum Vaccin Immunother
Stirling DC, de Miguel Ferrer M, Kim S, Wane M, Kysh D, Caproni LJ, Tregoning JS.   +6 more
europepmc   +1 more source

What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?

Biotechnology and Bioengineering, EarlyView.
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady, Nicholas Donohue, Alexandra Bogdanovic, Sharon Davin, Brian Glennon, Niall Barron, C. Mark Smales   +6 more
wiley   +1 more source